Kairos Pharma
KAPAKairos Pharma, Ltd. is a clinical-stage biopharmaceutical company focused on developing therapeutics to overcome immune suppression and drug resistance in cancer patients.
Earnings
Next report
Nov 13, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company focused on developing therapeutics to overcome immune suppression and drug resistance in cancer patients. The company leverages molecular insights to target key mechanisms of therapeutic resistance through a diversified portfolio of antibodies and small molecules. Its core value proposition lies in its proprietary technologies licensed from Cedars-Sinai Medical Center, aimed at transforming treatment for prostate, lung, breast, and brain cancers.
A clinical-stage innovator utilizing a virtual operational model to advance a seven-drug pipeline licensed from top-tier academic institutions.
FAQ
- What is Kairos Pharma's market cap?
- Kairos Pharma (KAPA) has a market capitalization of $6.2M and trades on XASE.
- Who are Kairos Pharma's competitors?
- Kairos Pharma's key competitors include Xilio Therapeutics, Inc. Common Stock, Nektar Therapeutics, Immunome, Inc., and others. These companies compete in similar markets and product categories.
- Who does Kairos Pharma partner with?
- Kairos Pharma's notable partners include Cedars-Sinai Medical Center, Tracon Pharmaceuticals, Inc., Pfizer, and others.
- Where is Kairos Pharma headquartered?
- Kairos Pharma is headquartered in United States of America. It has been publicly traded since 2024.